Kymera Therapeutics, Inc.’s (KYMR) Upgraded to Buy Following Positive Phase 1 Results for Oral STAT6 Degrader
B. Riley raised Kymera Therapeutics, Inc.’s (NASDAQ:KYMR) price target from $38 to $60, upgrading it from Neutral to Buy on June 3, 2025.
Kymera Therapeutics Inc. (KYMR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 6,460,000 | $176,810,200 | +26% | 2.76% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 5,995,929 | $164,108,577 | 1.82% | |
| 3. | Biotechnology Value Fund / BVF Inc Mark Lampert | 5,161,801 | $141,278,493 | 5.76% | |
| 4. | Siren L.L.C. Raymond Debbane | 3,240,313 | $88,687,367 | +10% | 5% |
| 5. | Driehaus Capital Richard Driehaus | 1,168,791 | $31,989,810 | -16% | 0.31% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $46.41 | 1 | $46.41 | 5,516,986 | 2024-08-20 | Filing | |
| $14.07 | 10,106 | $142,180.30 | 294,632 | 2023-11-03 | Filing | |
| $14.07 | 83,708 | $1,177,679.48 | 2,104,075 | 2023-11-03 | Filing | |
| $14.07 | 103,885 | $1,461,547.68 | 2,656,191 | 2023-11-03 | Filing | |
| $11.64 | 26,772 | $311,743.88 | 284,526 | 2023-11-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $50.00 | 4,500 | $225,000.00 | 0 | 2025-06-11 | Filing | |
| $49.04 | 5,000 | $245,185.50 | 0 | 2025-06-03 | Filing | |
| $47.00 | 4,800 | $225,600.00 | 0 | 2025-06-03 | Filing | |
| $45.50 | 7,200 | $327,600.00 | 4,800 | 2025-06-03 | Filing | |
| $49.00 | 30,000 | $1,470,000.00 | 660,482 | 2025-06-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,996,873 | $164,134,413 | 0.03% | |
| 2. | 5,231,392 | $143,183,198 | 0% | |
| 3. | 4,896,462 | $134,016,165 | 25.69% | |
| 4. | 4,409,234 | $120,680,747 | 0.01% | |
| 5. | 4,282,903 | $117,223,054 | 0% |
News See All
Morgan Stanley Maintains Hold Rating on Kymera Therapeutics (KYMR), Keeps PT
On June 2, analyst Vikram Purohit from Morgan Stanley maintained a Hold rating on Kymera Therapeutics, Inc. (NASDAQ:KYMR) with a price target of $49.
Citi Raises Kymera (KYMR) Price Target After Positive Drug Data, Keeps Buy Rating
On Monday, June 2, Citi analysts increased the price target on Kymera Therapeutics, Inc. (NASDAQ:KYMR) from $52 to $60 and kept a “Buy” rating.
BofA Upgrades Kymera Therapeutics (KYMR) to Buy, Lifts PT to $51
Earlier during the company's May 9 earnings call, Kymera indicated a strong financial position with $775 million in cash, which would extend the company's operational runway into H1 2028.
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Clinical Trial of KT-621
On June 2, Kymera Therapeutics Inc. (NASDAQ:KYMR) announced positive first-in-human results from its Phase 1 healthy volunteer clinical trial of KT-621, which is a first-in-class, oral STAT6 degrader.
Why Kymera Therapeutics, Inc. (KYMR) Skyrocketed On Monday
We recently published a list of These 10 Stocks Blew Past Expectations.
Kymera Therapeutics, Inc. (KYMR) to Announce KT-621 Phase 1 Results on June 2, 2025
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is set to unveil results from its Phase 1 clinical trial of KT-621, a first-in-class oral STAT6 degrader, on Monday, June 2, 2025.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript
Justine Koenigsberg: Good morning, and welcome to Kymera Therapeutics, Inc.'s Immunology Innovation Day, our virtual event to introduce our next immunology program, IRAF5.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2024 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2024 Earnings Call Transcript February 27, 2025Kymera Therapeutics, Inc. misses on earnings expectations.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Kymera Therapeutics Third Quarter 2024 Results Conference Call. All participants will be in listen-only mode.
Billionaire Hedge Funds
